In this webinar, we present the best practices of amyloid PET imaging and the most recent developments in the tau PET imaging space, including quantitative and visual assessment paradigms per the latest FDA approval. We examine imaging of neurodegeneration and also explore emerging biomarkers beyond N. Techniques such as bi-compartment diffusion modeling, quantitative susceptibility mapping (QSM), arterial spin labeling (ASL), and breath-hold fMRI are capable of being deployed in a large-scale clinical trial setting and could aid patient selection and demonstrate therapeutic benefit. We also highlight emerging PET markers for α-synuclein, microgliosis, and synaptic density, and their role in further refining AD staging.

The webinar also explores how the multi-modal integration of molecular imaging, MRI, and fluid biomarkers can provide a robust ability to accurately parse patients along the AD cascade to provide optimal classification and treatment strategies as well as therapeutic efficacy.

View Resource